The demand outlook for Biogen’s new Alzheimer’s drug appears strong despite lingering concerns about the new treatment, and that should push the company’s stock higher, according to Piper Sandler. The...
Source LinkThe demand outlook for Biogen’s new Alzheimer’s drug appears strong despite lingering concerns about the new treatment, and that should push the company’s stock higher, according to Piper Sandler. The...
Source Link
Comments